VRNA - ベロナ・ファ―マ (Verona Pharma plc) ベロナ・ファ―マ

 VRNAのチャート


 VRNAの企業情報

symbol VRNA
会社名 Verona Pharma Plc (Adderbury) (ベロナ・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種    医療関連(Health Care)
概要 事業概要 --   ベロナ・ファ―マはイギリスの製薬会社。主に慢性呼吸器疾患の治療用医薬品の開発・商品化に従事する。主に慢性閉塞性肺疾患(COPD)、ぜんそく、咳などの治療に焦点を当て、同社開発中の新薬は「RPL554」、「VRP700」と「NAIPs」の3種類を含む。本社所在地は英国ウェ―ルズ・カ―ディフ。   Verona Pharma Plc operates as a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases. It's product include, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The firm develops RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, United Kingdom.
本社所在地 One Central Square Cardiff CF10 1FS GBR
代表者氏名
代表者役職名
電話番号
設立年月日 38384
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 7人
url www.veronapharma.com/
nasdaq_url https://www.nasdaq.com/symbol/vrna
adr_tso 9182592
EBITDA EBITDA ー
終値(lastsale) 12.93
時価総額(marketcap) 118730914.56
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 VRNAのテクニカル分析


 VRNAのニュース

   FY2019 EPS Estimates for VERONA PHARMA P/S Raised by Wedbush (NASDAQ:VRNA)  2019/11/08 12:50:42 Modern Readers
VERONA PHARMA P/S (NASDAQ:VRNA) – Equities researchers at Wedbush upped their FY2019 earnings estimates for shares of VERONA PHARMA P/S in a research note issued on Tuesday, November 5th. Wedbush analyst L. Moussatos now expects that the company will post earnings of ($3.46) per share for the year, up from their previous estimate of ($3.48). […]
   The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug  2019/07/11 10:17:30 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 10) CONMED Corporation (NASDAQ: CNMD ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Enlivex Therapeutics Ltd (NASDAQ: ENLV ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Penumbra Inc (NYSE: PEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) ( announced a restructuring plan, and also reduced full-year adjusted EBITDA guidance) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Jaguar Health Inc (NASDAQ: JAGX ) VERONA PHARMA P/S ADR (NASDAQ: VRNA ) See Also: Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates Stocks In Focus Neurocrine Says FDA Accepts Regulatory Filing For Parkinson's Drug Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) said the FDA has accepted its NDA for opicapone, a once-daily, oral, selective catechol-O-methyltransferase inhibitor as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease …
   The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO  2019/06/28 11:32:52 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on June 27) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) (received fast track designation for its RNAi therapeutic for rare genetic liver disease associated with alpha-1 antitrypsin deficiency) Odonate Therapeutics Inc (NASDAQ: ODT ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repligen Corporation (NASDAQ: RGEN ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on June 27) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) ( said its hair loss drug candidate did not meet primary or secondary endpoints) Caladrius Biosciences Inc (NASDAQ: CLBS ) Kaleido Biosciences Inc (NASDAQ: KLDO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Neurometrix Inc (NASDAQ: NURO )(announced a strategic update in which it divulged plans to carry out restructuring) Sellas Life Sciences Group Inc (NASDAQ: SLS ) VERONA PHARMA P/S ADR (NASDAQ: VRNA ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus On The Radar Chiasma To Join the Broader Russell 3000 Index Chiasma Inc (NASDAQ: CHMA ) announced it has been selected for inclusion in the broad-based Russell 3000 Index, effective July 1.
   Verona Pharma (VRNA) Presents At American Thoracic Society International Conference - Slideshow  2019/05/20 19:04:56 Seeking Alpha
   Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q1 2019 Results - Earnings Call Transcript  2019/05/13 03:52:09 Seeking Alpha
Verona Pharma plc (NASDAQ:VRNA) Q1 2019 Results Earnings Conference Call May 07 2019, 08:00 AM ET Company Participants Stephanie Carrington - Investor Relations
   Verona Pharma nabs additional patent in Europe  2019-04-09
The European Patent Office has granted Verona Pharma (NASDAQ: VRNA ) an additional key patent relating ensifentrine. More news on: Verona Pharma plc, Verona Pharma plc, Healthcare stocks news, Read more …
   Verona Pharma nabs additional patent in Europe  2019-04-09
The European Patent Office has granted Verona Pharma (NASDAQ: VRNA ) an additional key patent relating ensifentrine. More news on: Verona Pharma plc, Verona Pharma plc, Healthcare stocks news, Read more …

 関連キーワード  (― 米国株 ベロナ・ファ―マ VRNA Verona Pharma plc)

 twitter  (公式ツイッターやCEOツイッターなど)